Annual report pursuant to Section 13 and 15(d)

Inventory

v3.20.4
Inventory
12 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
Inventory

(6)

Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. The Company expensed costs related to inventory within the Research and development line in the Consolidated and Combined Statements of Operations until it received approval from the FDA to market a product, at which time the Company commenced

capitalization of costs relating to that product. Adjustments to inventory are determined at the raw material, sub-assemblies and finished goods levels to reflect obsolescence or impaired balances.

Inventory was as follows:

 

 

 

December 31, 2020

 

 

December 31, 2019

 

Raw materials

 

$

130

 

 

$

 

Sub-assemblies

 

 

2,476

 

 

 

 

Finished goods

 

 

928

 

 

 

 

 

 

 

3,534

 

 

 

 

Provision for inventory obsolescence

 

 

(556

)

 

 

 

 

 

$

2,978

 

 

$